SCHEMBL29332196

SCHEMBL29332196

C#Cc1c(-c2ccc(OC)c(OC)c2)cc(-c2ccc(F)cc2)[nH]c1=N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 1/20 0.43
▸ SLC10A2 Q12908 1/20 0.41
▸ KIT P10721 3/20 0.41
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ USP2 O75604 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29335410 0.88 KDM4E (0.49) TNKSSLC10A2KITMEN1KMT2A
SCHEMBL29331866 0.80 MAPK14 (0.49) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL29332195 0.79 IL4 (0.43) KMT2AMAPTKDM4EALDH1A1GAA
SCHEMBL31695295 0.78 KDM4E (0.48) TNKSMEN1KMT2AMAPTKDM4E
SCHEMBL31695335 0.78 KDM4E (0.59) TNKSMEN1KMT2AMAPTKDM4E
SCHEMBL29331867 0.75 MAPT (0.46) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL29331948 0.74 SQOR (0.53) TNKSMEN1KMT2AMAPTKDM4E
SCHEMBL29331869 0.74 MAPK14 (0.38) KITGSK3BGCGRMAPK14
SCHEMBL29331889 0.73 MEN1 (0.43) MEN1KMT2AMAPTALDH1A1POLB
SCHEMBL29331870 0.72 KDM4E (0.64) SLC10A2MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043621-B2 Small molecule inhibitors of Interleukin-4 TRUSTEES OF BOSTON UNIVERSITY (US) 2024-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043621-B2 Small molecule inhibitors of Interleukin-4 IL4, IL2, IL4I1 TNKS 1357/4885SLC10A2 4705/4885KIT 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback